circle-image

Short

Trend Resistance

Uptrend Above: 24350

Bull Signal Above: 24410
circle-image

Term

Trend Point Acts

Trend Point: 24330

My PCR: 1.02
44 Range 126

Up Trend Signal

circle-image

View

Trend Suport

Down Below: 24310

Bear Signal Below: 24240
Short Term View Historic Data

Nifty View On: Monday 17 Aug 2026

Day Close

24366
Day High

24405
Day Low

24296
Day Avg

24356
14 Aug 2026
5 SMA

24450
10 SMA

24547
20 SMA

24323
50 SMA

24084
200 SMA

24730
5 EMA

24406
10 EMA

24454
20 EMA

24335
50 EMA

24215
Monday View
Resist 2

24480
Resist 1

24420
Mid Point

24370
Suport 1

24310
Suport 2

24260
52W High

26373
52w Low

22182
52w Down

7.61%
52w Up

9.85%
Panic View
Resist 2

24580
Resist 1

24500
Mid Point

24370
Suport 1

24230
Suport 2

24150
5d High

24620
5d Low

24265
10d High

24774
10d Low

24265
Days High & Low 20d High

24774
20d Low

23606
50d High

24774
50d Low

23070
All Avg

24269
FFTH

24553
FTTL

24435
TTTH

24604
TTTL

24215
High & Low Avg TTFH

24385
TFFL

23817
High Avg

24514
Low Avg

24156
All Avg

24335
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 14 Aug 2026 24366 24405 24296 24450 24547 24323 24084 24730
2 13 Aug 2026 24395 24431 24311 24491 24549 24321 24065 24738
3 12 Aug 2026 24435 24473 24265 24539 24541 24305 24045 24745
4 11 Aug 2026 24471 24576 24429 24577 24522 24287 24026 24752
5 10 Aug 2026 24583 24620 24511 24605 24474 24266 24004 24758
Nifty Historic Data And Moving Avg

Go Back

Morepen Laboratories Limited Amount and percentage of the turnover or revenue or income and net...

Posted: 14 Jan 2025

Morepen Laboratories Limited Amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year The details of turnover and net worth of Medical Devices Business as on March 31, 2024, are mentioned below: b) Date on which the agreement for sale has been entered into Subject to receipt of requisite regulatory and membersapprovals, the Board of Directors of the company hasapproved the sale of the Medical Devices Business of the company to Morepen Medtech Limited, a subsidiary company, as going concern on slump sales basis today i.e.January 14, 2025, including authorising the directors/ officers of the Company to enter the Business TransferAgreement (BTA) and other related documents to give effect to the transaction. The BTA will be executed in due course and will be informed to the Stock Exchanges separately. c) Expected date of completion of sale/disposal The completion of the slump sale of the Medical Devices Business is expected to be completed on or before September 30, 2025, subject to receipt of requisite regulatory and other approvals and fulfilment of customary conditions precedent and in accordance with the provisions of the BTA. d) Consideration received from such sale/disposal The consideration for such slump sale will be derived on the basis of the report of the independent valuer in respect of Building and Plant & Machinery, net current assets, other non-current assets and liabilities as per the Balance Sheet as on effective date of transfer of Medical Devices Business and will also be in compliance with Rule 11 UAE of Income Tax Rules 1962. e) Brief details of buyers and whether any of the buyers belong to the promoter/ Morepen Medtech Limited, is a public company (subsidiary of Morepen Laboratories Limited), incorporated on January 8, 2025, to carry on the business of medical devices. Morepen Laboratories Limited CIN NO. L24231 HP1984PLC006028 Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com promoter group/ group companies. If yes, details thereof Yes, Morepen Medtech Limited has been incorporated as a subsidiary of the company, with an aggregate shareholding of 20% of the entities belonging to the promoters group/ relatives of promoter/ members of promoter group. f) Whether the transaction would fall within related party transactions? If yes, whether the same is done at arms length? Yes, the transaction qualifies as a related party transaction and is being conducted on an arms length basis. Furthermore, the company will obtain approval from themembers. g) Whether the sale, lease or disposal of the undertaking is outside the Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations. Yes, the transaction is outside the Scheme of Arrangement.In compliance with Regulation 37A of the SEBI Listing Regulations the Medical Devices Business being anundertaking in terms of the provisions of the Companies Act, 2013, the company will seek the approval of the members of the company. h) Additional disclosures in case of a slump sale i. name of the entity(ies) forming part of the slump sale amalgamation/ merger, details in brief such as, size, turnover etc. Seller: Morepen Laboratories Limited Audited financial details as of March 31, 2024: Particulars Turnover (? in Lakh) Percentage Net worth (? in Lakh) Percentage Other Pharmaceutical Business* 1,24,771.66 73.81% 74,363.57 89.12% Medical Devices Business 44,271.59 26.19% 9,078.52 10.88% Total 1,69,043.25 100.00% 83,442.09 100.00% *Consolidated basis. Buyer: Morepen Medtech Limited, a subsidiary of Morepen Laboratories Limited, as incorporated on January 8, 2025, with the paid-up capital of ? 10,00,000/- (Rupees Ten Lakh Only). ii. whether the transaction would fall within related party transactions? If yes, whether the same is done at arms length Refer point no. (f) above.

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.